Core Viewpoint - The article discusses the conflict between Huaxi Biological and several brokerage firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is misleading and driven by "restless capital" [1][7]. Company Overview - Huaxi Biological specializes in hyaluronic acid-related products and has faced significant stock price and market capitalization declines since reaching a peak in July 2021, with its stock price dropping from 313.1 yuan to 52.61 yuan as of May 21, 2023, resulting in a market cap reduction from over 1500 billion yuan to 253 billion yuan [2][8]. - The company has reported continuous revenue declines, with revenues of 60.76 billion yuan and 53.71 billion yuan for 2023 and 2024, respectively, representing year-on-year decreases of 4.45% and 11.61% [10]. Industry Dynamics - The market has seen a shift in focus towards recombinant collagen protein, with companies like Juzhi Biological and Jinbo Biological experiencing significant stock price increases and revenue growth, contrasting with Huaxi's struggles [2][13]. - The recombinant collagen protein market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 585.7 billion yuan by 2025 [7]. Performance Comparison - Juzhi Biological's revenues for 2022, 2023, and 2024 were 23.75 billion yuan, 35.26 billion yuan, and 55.39 billion yuan, respectively, with year-on-year growth rates around 50% [13]. - Jinbo Biological's revenues during the same period were 3.9 billion yuan, 7.8 billion yuan, and 14.43 billion yuan, with growth rates of 67.15%, 99.97%, and 84.92% [13]. Regulatory and Market Response - Huaxi Biological has reported the brokerage firms to the China Securities Regulatory Commission for allegedly misleading reports that could distort market perceptions [1][3]. - The company has emphasized the need for a healthy industry ecosystem and has engaged with industry associations to advocate for a return to scientific principles in the market [5][7].

Core Viewpoint - Huaxi Biological has publicly criticized several securities firms for promoting collagen products and suggesting that hyaluronic acid is "outdated," indicating a defensive stance amid declining performance and market competition [1][2][3] Company Performance - Huaxi Biological started with hyaluronic acid and holds nearly 50% of the global market share, expanding into medical products, skincare, and functional foods [5][6] - Despite maintaining positive growth during the pandemic years of 2020 and 2021, the company's revenue and profit have declined since 2021, with net profits projected to drop from 9.71 billion yuan in 2022 to 1.74 billion yuan in 2024 [10] - The company's market capitalization has plummeted from over 140 billion yuan in 2021 to 25.3 billion yuan as of May 21, 2025 [10] Market Comparison - In contrast, competitors like Juzhi Biological and Jinbo Biological have seen significant growth, with Juzhi's net profits increasing from 1 billion yuan in 2022 to 20.62 billion yuan in 2024, and Jinbo's from 1.09 billion yuan to 7.31 billion yuan in the same period [14] - Both companies have also achieved substantial stock price increases, with market capitalizations of 87.5 billion HKD and 51.1 billion yuan, respectively [14] Industry Dynamics - The rise of collagen products has created a competitive threat to hyaluronic acid, with market trends favoring new ingredients [15][18] - The demand for collagen is expected to exceed supply, with projections indicating a production of 200,000 tons against a demand of over 220,000 tons by 2025 [19] Challenges Ahead - Despite Huaxi's efforts to defend hyaluronic acid, the company faces challenges due to internal management issues and a tarnished brand image, which may hinder future sales growth [20][21] - The company's recent foray into collagen products has not yet shown significant revenue impact, suggesting ongoing struggles in adapting to market changes [21]

Group 1: Industry Dynamics - The medical beauty industry is experiencing a shift from technology competition to capital narrative, as highlighted by Huaxi Biological's recent criticism of major brokerages for downplaying hyaluronic acid in favor of collagen products [2][7] - The market for hyaluronic acid is becoming increasingly competitive, with over 50 approved Class III medical devices and more than 400 circulating brands in China by 2024, leading to a saturation of supply [8][9] - Emerging alternative materials, such as hydroxyapatite and recombinant collagen, are reshaping the market landscape, with predictions that the collagen market in China will reach 173.8 billion yuan by 2027, with recombinant collagen accounting for over 60% [9][6] Group 2: Company Performance - Huaxi Biological's revenue declined from 6.359 billion yuan in 2022 to 5.371 billion yuan in 2024, with net profit dropping from 961 million yuan to 174 million yuan, and a further 58.13% decrease in Q1 2025 net profit year-on-year [7][10] - Aimei Ke's revenue growth slowed to a historical low of 5% in 2024, with its flagship product "Hi Body" achieving 314 million yuan in sales, but injection product growth rates fell to single digits [7] - Haohai Biological's revenue for 2024 was 2.698 billion yuan, a slight increase of 1.64%, but its ophthalmology and orthopedics businesses faced significant declines due to centralized procurement policies [7] Group 3: Marketing Strategies - The marketing strategies in the medical beauty sector are evolving, with institutions leveraging consumer psychology to shift focus from hyaluronic acid to collagen products, promoting the latter as safer and more effective [5][4] - Social media plays a crucial role in shaping consumer perceptions, with narratives around collagen's benefits and the risks associated with hyaluronic acid injections driving consumer behavior [5][4] - The pricing dynamics show that while hyaluronic acid injections are becoming more affordable, collagen injections remain significantly more expensive, creating a new revenue opportunity for institutions [4][6]

Core Viewpoint - The article highlights a conflict in the biopharmaceutical industry regarding the competition between hyaluronic acid and recombinant collagen, with Huaxi Biological criticizing the notion that hyaluronic acid is outdated, which they attribute to capital-driven speculation [1][4]. Company Performance - Huaxi Biological's performance has declined significantly, with projected revenue for 2024 expected to decrease by 11.61% and net profit to drop by 70.59%, resulting in a market capitalization loss of over 100 billion [1][6]. - In contrast, Juzhi Biological has experienced substantial growth, with a projected revenue increase of 57.2% and net profit growth of 42.4% for 2024, leading to a doubling of its market capitalization [1][6]. Market Dynamics - The article discusses the contrasting market performances of Huaxi Biological and Juzhi Biological, indicating a clear divide in the industry, with Huaxi's stock price falling over 80% from its peak of 309.43 yuan per share in July 2021 to 53.08 yuan per share as of May 20, 2025, resulting in a market cap of less than 25.6 billion [9][6]. - Juzhi Biological's stock has seen a significant increase, reaching a peak of 86.45 HKD, representing a cumulative rise of over 44% from approximately 60 HKD at the end of 2024 [8][6].

Core Viewpoint - The article highlights the conflict between Huaxi Biological and several brokerage firms that support Juzi Biological, criticizing the notion that sodium hyaluronate is outdated and emphasizing the ongoing relevance of hyaluronic acid in the beauty and medical aesthetics industry [1][3]. Company Performance - Huaxi Biological's market capitalization has significantly decreased from over 140 billion yuan in 2021 to approximately 25 billion yuan currently, while Juzi Biological's stock has surged nearly 70% in 2024, elevating its founders to the status of the richest individuals in Shaanxi [2]. - In 2024, Huaxi Biological reported its worst performance since going public, with annual revenue of 5.371 billion yuan, a decline of 11.6% year-on-year, and a net profit of 164 million yuan, down 72.27% [2]. - Juzi Biological, in contrast, has shown robust growth since 2019, with 2024 revenue reaching 5.539 billion yuan, a year-on-year increase of 57.17%, and a net profit of 2.062 billion yuan, up 42.06% [2]. Market Trends - The market is increasingly favoring the field of recombinant collagen due to its excellent biocompatibility and biodegradability, with projections indicating that the collagen-based skincare market may surpass that of hyaluronic acid by 2026, with a compound annual growth rate of 52.6% [3]. - Despite the rise of recombinant collagen, hyaluronic acid remains irreplaceable in the medical aesthetics sector, particularly in filling procedures, and Huaxi Biological continues to hold a competitive edge in this area [3]. Industry Dynamics - Several brokerage firms, including Huafu Securities and Debon Securities, have retracted their reports that were criticized by Huaxi Biological, indicating the contentious nature of the market's perception of recombinant collagen [4]. - The development of recombinant collagen is still in its early stages, with high raw material costs and insufficient research on its applications, suggesting that both hyaluronic acid and recombinant collagen may coexist in the market to meet diverse consumer needs [4].

Core Viewpoint - The article discusses the ongoing debate regarding the relevance of hyaluronic acid (HA), with Huaxi Biotech refuting claims that HA is outdated and emphasizing its continued importance in life sciences research [1][2]. Group 1: Market Perspective - Huaxi Biotech directly addresses nine brokerage firms that have published reports suggesting that hyaluronic acid is becoming obsolete, labeling this perspective as a product of "restless capital" creating a false narrative [1]. - The company argues that the rise of the "outdated hyaluronic acid" theory is fundamentally a misrepresentation of a substance that has been central to life sciences for millions of years [1]. Group 2: Research and Development - Since the discovery of HA, the number of related studies has been increasing annually, with a significant surge post-2010, where over 60% of research focuses on cutting-edge areas such as immunity, metabolism, and cell differentiation [1]. - Huaxi Biotech's breakthrough enzyme cutting technology in 2011 has significantly advanced research on hyaluronic acid in fields like cancer, aging, and immunity [1]. Group 3: Future Outlook - The company expresses its commitment to leveraging its foundation in the sugar biology industry to explore deeper realms of life sciences, asserting that hyaluronic acid will always be their starting point [2]. - Huaxi Biotech emphasizes the importance of protecting the industry built over generations and is open to discussions on optimizing scientific and industrial ecosystems [2].

Investment Rating - The report maintains a recommendation for the beauty and personal care industry, highlighting the continued growth of leading domestic brands [2]. Core Insights - The beauty and personal care sector has shown a divergence in performance, with leading domestic brands achieving good growth due to their competitive pricing, differentiated products, and effective online operations [1][10]. - The upcoming 618 shopping festival is expected to further catalyze growth for domestic brands, particularly in the cosmetics sector [1][6]. Summary by Sections Cosmetics - In 2024 and Q1 2025, leading domestic brands continued to show strong growth, with significant revenue increases reported: - Molybdenum Biological: +33% revenue, +32% net profit - Giant Biological: +57% revenue, +42% net profit - Upper Beauty: +62% revenue, +69% net profit [11][13]. - The overall performance of the cosmetics sector is characterized by a mix of growth and decline among various companies, with some like Proya showing resilience in profit despite revenue slowdowns [12][13]. - The report suggests focusing on brands with strong single-product strategies and innovative ingredients, such as Giant Biological and Molybdenum Biological, as well as those with strong brand positioning like Mao Geping [1][6]. Personal Care - The personal care segment has seen robust performance from leading domestic brands, with notable revenue growth in Q1 2025: - Baiya: +30% - Stable Medical: +36% - Hao Yue Care: +42% [6][12]. - The report emphasizes the importance of product upgrades and channel expansion for these brands, which have outperformed OEM companies [1][6]. - The ongoing trend of online expansion and the shift towards mid-to-high-end branding remains strong, with companies like Baiya and Stable Medical showing promising developments [6][12]. Market Trends - The overall market for cosmetics in early 2025 showed a slight increase in retail sales, with a year-on-year growth of 4.0% in the first four months [23]. - Online platforms like Tmall and Douyin have seen varying performance, with Douyin showing higher growth rates in certain categories compared to Tmall [26][29]. Key Brand Performance - Key brands have demonstrated significant growth in both Tmall and Douyin platforms, with notable increases in GMV for brands like Mao Geping and Kefu Mei [33]. - The report highlights the competitive landscape, with domestic brands increasingly capturing market share from international brands due to their pricing and innovative marketing strategies [1][6].

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the healthcare sector [3][4]. Group 1: Market Performance - As of May 21, 2025, the HSHCI rose by 3.00%, with notable gains from stocks such as Ascentage Pharma-B (up 10.17%) and 3SBio (up 7.92%) [3]. - The Hang Seng Healthcare ETF (513060) increased by 1.60%, marking its fourth consecutive rise, with a latest price of 0.51 yuan [3]. - The ETF's trading volume reached 5.98 billion yuan, with a turnover rate of 5.97% [3]. Group 2: Company Developments - 3SBio announced a partnership with Pfizer, granting exclusive rights for the global development and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707, excluding mainland China [3]. - 3SBio retains rights for SSGJ-707 in mainland China and will grant Pfizer an option for commercialization in that region based on agreed financial terms [3]. Group 3: Industry Trends - The Chinese innovative drug market is projected to grow from $132.5 billion in 2019 to $159.2 billion by 2024, maintaining a global market share of around 15% [4]. - In 2024, China completed 94 license-out transactions for innovative drugs, totaling $51.9 billion, a 26% increase year-on-year [4]. - The focus on platform technologies such as ADCs, bispecific antibodies, and gene editing is increasing among multinational corporations (MNCs), highlighting the growing recognition of Chinese innovative drugs [4]. Group 4: ETF Performance Metrics - The latest size of the Hang Seng Healthcare ETF is 9.859 billion yuan, ranking it in the top third among comparable funds [5]. - The ETF has achieved a 26.90% net value increase over the past year, with a maximum monthly return of 28.34% since inception [5]. - The ETF's Sharpe ratio stands at 1.12, ranking it in the top half among comparable funds, indicating high returns relative to risk [5]. Group 5: Valuation Insights - The HSHCI's current price-to-earnings ratio (PE-TTM) is 24.38, indicating it is at a historical low, below 90.91% of the time over the past year [6]. - The top ten weighted stocks in the HSHCI account for 57.2% of the index, with companies like WuXi Biologics and Innovent Biologics among the leaders [6].

服装丨市场观察 本周看点： -老铺黄金火了，「周大福们」跟上了吗？ -奢侈品牌如何为"超级贵宾"打造不一样的 VIC 空间？ -国货美妆2024年业绩拆解，50亿成为TOP6新门槛。 行业环境 1.老铺黄金火了，「周大福们」跟上了吗？ 关键词：黄金珠宝,古法工艺,高端商场,年轻消费,文化审美 概要：老铺黄金凭借"古法黄金"工艺创新、高端商场布局及VIP服务体验，在金价上涨背景下 逆势崛起，24年36家门店实现85亿元营收。创始人徐高明将其定位为奢侈品品牌，对标爱马 仕，目标单店年销售额超10亿元。品牌吸引年轻消费者与高净值人群，会员年内增长至35万。 老铺黄金计划拓展国际市场，推动全品类黄金奢侈品发展，形成与周大福等品牌的良性竞争。 2.飞速涨粉的"服饰成分党"博主，靠讲面料破圈了？ 关键词：服饰成分,面料分析,服装博主,理性消费,品质生活 概要：新一代"服饰成分党"博主以面料、版型为核心，科普服装材质优劣与选购技巧，多为行 业资深从业者。他们通过分析纤维成分、缝线工艺等细节，帮助消费者规避购买误区，获大量 关注。代表如"十一讲服装"和"Tina面料测评"。相比传统博主，更注重专业性和实用性，满足 年轻女性对 ...

Summary of Key Points from Conference Call Records Industry Overview - The consumer sector in China is exhibiting a "weak beta alpha" characteristic in 2025, making it easier for institutional investors to identify individual stock opportunities, particularly in the beauty and personal care segment which has seen significant gains due to favorable policies and market recovery [1][4] - The consumer industry is experiencing notable sub-sector differentiation, with emerging consumption trends in areas such as pet products, skincare, and IP-related products performing well, while traditional sectors like certain liquor and seasoning products are declining [1][5] Core Insights and Arguments - The food and beverage industry is showing clear signs of differentiation, with health products like ergothioneine gaining popularity, and the dairy sector potentially reversing its cycle as milk prices are expected to rise [1][6][7] - The small food sector is also experiencing structural differentiation, with companies like Youyou Foods and Yanjin Puzhi leveraging new channels, while innovative categories like konjac products are gaining attention [1][8] - The beauty and home care segment is performing strongly, with companies such as Juzhi Biotechnology, Shangmei Runben, and others expected to see growth rates of around 30% [1][10] Emerging Trends - The agricultural market is focusing on four main areas: the pet market with high growth rates, the reversal of the meat and dairy cycle, post-breeding cycles, and animal health companies [1][12] - The潮玩 (trendy toy) industry is benefiting from interest-driven consumption trends, with leading IPs expanding their market presence. Companies like Pop Mart are recommended due to their comprehensive industry chain layout and successful overseas market penetration [1][13][14] Additional Important Insights - The chain discount sector is improving efficiency by eliminating intermediaries, leading to lower prices and smoother distribution, with companies like COPA and Wan Cheng showing potential [1][9] - The home care product competitive landscape is changing significantly, with new entrants like Duowei sanitary napkins achieving high sales on launch [1][11] - The tea beverage sector is seeing a resurgence, with frequent IPOs and strong performance from leading companies like Mixue Ice City, which is expanding its market presence [1][15] Investment Opportunities - The home appliance industry is witnessing opportunities driven by technological innovation, particularly in AI applications and robotics, with companies like Midea and Gree leading the charge [1][16][17][18] - Other new consumption sectors worth noting include capital economy-related stocks and the electronic cigarette market, as well as various "AI+" related segments [1][19] Conclusion - The overall sentiment in the consumer sector is positive, with various sub-sectors showing potential for growth and investment opportunities, driven by changing consumer preferences and favorable economic policies [2][3]